Fusion Antibodies PLC (FAB) - Total Liabilities

Latest as of September 2025: GBX1.09 Million GBX ≈ $132.13 USD

Based on the latest financial reports, Fusion Antibodies PLC (FAB) has total liabilities worth GBX1.09 Million GBX (≈ $132.13 USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See working capital to net assets of Fusion Antibodies PLC to evaluate short-term liquidity relative to the company's equity base.

Fusion Antibodies PLC - Total Liabilities Trend (2006–2025)

This chart illustrates how Fusion Antibodies PLC's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Fusion Antibodies PLC's balance sheet.

Fusion Antibodies PLC Competitors by Total Liabilities

The table below lists competitors of Fusion Antibodies PLC ranked by their total liabilities.

Company	Country	Total Liabilities
Cambridge Cognition Holdings Plc LSE:COG	UK	GBX9.40 Million
I.Ceram SA PA:ALICR	France	€3.48 Million
Tavistock Investments Plc LSE:TAVI	UK	GBX12.56 Million
Virgin Wines UK PLC LSE:VINO	UK	GBX18.50 Million
LMS Capital Plc LSE:LMS	UK	GBX1.22 Million
Lexington Gold Ltd LSE:LEX	UK	GBX631.23K
Meyer Burger Tech AG SW:MBTN	Switzerland	CHF545.59 Million

Liability Composition Analysis (2006–2025)

This chart breaks down Fusion Antibodies PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See FAB net asset quality score to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.80	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.50	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.60	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Fusion Antibodies PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Fusion Antibodies PLC (2006–2025)

The table below shows the annual total liabilities of Fusion Antibodies PLC from 2006 to 2025.

Year	Total Liabilities	Change
2025-03-31	GBX654.00K ≈ $79.57	+4.31%
2024-03-31	GBX627.00K ≈ $76.29	-33.23%
2023-03-31	GBX939.00K ≈ $114.25	-23.72%
2022-03-31	GBX1.23 Million ≈ $149.78	+13.67%
2021-03-31	GBX1.08 Million ≈ $131.77	-11.81%
2020-03-31	GBX1.23 Million ≈ $149.41	+38.21%
2019-03-31	GBX888.53K ≈ $108.11	+40.24%
2018-03-31	GBX633.59K ≈ $77.09	+40.73%
2017-03-31	GBX450.22K ≈ $54.78	+9.43%
2016-03-31	GBX411.43K ≈ $50.06	+104.01%
2015-03-31	GBX201.67K ≈ $24.54	-32.23%
2014-03-31	GBX297.57K ≈ $36.21	+17.35%
2013-03-31	GBX253.56K ≈ $30.85	-42.76%
2012-03-31	GBX443.00K ≈ $53.90	+15.97%
2011-03-31	GBX382.00K ≈ $46.48	+25.25%
2010-03-31	GBX305.00K ≈ $37.11	-51.82%
2009-03-31	GBX633.00K ≈ $77.02	+37.01%
2008-03-31	GBX462.00K ≈ $56.21	+3.36%
2007-03-31	GBX447.00K ≈ $54.39	+54.14%
2006-03-31	GBX290.00K ≈ $35.28	--

About Fusion Antibodies PLC

LSE:FAB UK Biotechnology

Market Cap

$154.88K

GBX1.27 Billion GBX

Market Cap Rank

#31392 Global

#1058 in UK

Share Price

GBX11.20

Change (1 day)

-0.44%

52-Week Range

GBX9.25 - GBX19.25

All Time High

GBX213.00